- Home
- News
- latamerica
- antigen expression
Antigen Expression Articles & Analysis
33 news found
But the timeline for the development of some vaccine types is still grueling, spanning preclinical design, multiple trial phases, and complex manufacturing hurdles. With challenges like antigen selection, delivery optimization, and large-scale production, companies like Creative Biolabs are rare and indispensable partners for pharma and academic groups racing against the clock. ...
The platform covers both linear and conformational epitope analysis and includes the following core services: l Binding Activity Confirmation: ELISA or Western blot assays to verify the interaction between the submitted antibody and antigen. l Glycosylation Analysis (Optional): Comparing antibody binding to glycosylated versus deglycosylated forms of the ...
By keeping up with the latest advancements in the field, its team of expert scientists possesses a deep knowledge of RNA biology, viral vectors, antigen design, and delivery systems. This expertise allows them to design and develop highly effective and safe mRNA vaccine candidates. ...
Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has announced the launch of new reagent solutions for herpesvirus research, including a range of Human Herpesviruses Antibodies designed to help researchers better understand the structure of Herpesvirus entry and develop new treatments and prevention strategies. ...
Advances in cell replacement therapy, for example, are making it possible for scientists to genetically engineer a patient’s own T-cells so they can specifically target antigens expressed only on the surface of tumor cells. Similar innovations in regenerative medicine and stem cell therapy are likewise opening the way for potentially revolutionary ...
Creative Diagnostics' monkeypox virus antigens are expressed in E. coli or HEK293 cells and are manufactured at a purity level of > 90%, suitable for ELISA and lateral flow assays and can be used to develop diagnostic assays. ...
LOS ANGELES, CA – October 6, 2022 – T-Cure Bioscience, Inc., a privately held company focused on developing T cell receptor (TCR) therapy products for the treatment of solid tumors, today announced that the National Cancer Institute (NCI) and Rutgers University sites are open to recruit patients for the treatment of Kita-Kyushu lung cancer antigen 1 (KK-LC-1) ...
Lumen Bioscience pioneered genetic engineering methods to highly express bioactive proteins in spirulina. The published research details how this platform was used to express a malaria protein antigen that can be delivered intranasally and later boosted with a simple oral booster. ...
BillionToOne , Inc., a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, announces the launch of their UNITY fetal antigen single-gene non-invasive prenatal test (sgNIPT), a new addition to UNITY Screen. For pregnant patients who are alloimmunized with C, c, D, E, Duffy (Fya), or Kell (K) red blood cell (RBC) antibodies, this novel NIPT ...
HB-202 is a single-vector compound that uses Pichinde Virus as its arenaviral backbone. Both express the same antigen, an E7E6 fusion protein derived from HPV16. HB-202/HB-201 is an alternating 2-vector immunotherapy designed to further focus the immune response against the target antigen. ...
Design and rationale of the phase 1/2a open label, multicenter study of the AFM24 monotherapy in patients with advanced EGFR-expressing solid tumors Design and rationale of the phase 1/2a study of AFM24 in combination with atezolizumab in patients with advanced EGFR-expressing solid tumors Design and rationale of the phase 1/2a study of AFM24 in combination ...
As a global leading supplier of raw materials, antibodies, and reagents for bio-technology industry, Creative Diagnostics recently launches recombinant antigens p18 and p23 (viral capsid antigens, VCA), p54 and p138 (early antigens, EA) and EBNA1 (nuclear antigen, EBNA). These recombinant antigens in immunoassays ...
In vitro data demonstrate significant NOT GATE-mediated protection of primary healthy hematopoietic stem cell (HSC)-enriched cells from off-tumor toxicity via CAR-NK cell recognition of the HSC-expressed EMCN healthy antigen; in vivo data also demonstrate significant NOT GATE-mediated protection of healthy model cells from CAR-NK cell toxicity. ...
The paper entitled “A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through T cell-mediated immunity” shows that Ziphius’ multi-antigenic self-amplifying RNA COVID-19 vaccine candidate induces a potent humoral and cellular immune response at low ...
” About VAC2 VAC2 is an allogeneic, or non-patient specific “off-the-shelf,” cancer vaccine product candidate designed to stimulate patient immune responses to an antigen commonly expressed in cancerous cells but not in normal adult cells. VAC2, which is produced from a pluripotent cell technology using a directed differentiation method, is ...
TU-207) Engineered CAR-Treg Platform STEADFAST: A First-in-Human Study Assessing HLA-A*02-Chimeric Antigen Receptor Regulatory T Cells in Renal Transplantation Abstract No. 798 Poster Presentation – May 17; 5:30-6:30 pm ET (Board No. Tu-303) Engineering of Allogeneic T Regulatory Cells Expressing a Chimeric Antigen ...
It does this by delivering cancer-associated proteins — known as MAGE-A3 and NY-ESO-1 antigens — to antigen presenting cells (dendritic cells), causing the immune system to produce cytotoxic T cells which are able to target and kill cancer cells expressing these antigens. ...
Poster no. 2773: “Human Placental CD34+-Derived Natural Killer Cells with High Affinity and Cleavage Resistant CD16 (CYNK-101) in Combination with Daratumumab for Immunotherapy Against CD38 Expressing Hematological Malignancies” Session name: 703. Cellular Immunotherapies: Basic and Translational: Poster II Presentation date/time: Sunday, 12 December 2021; 6:00 pm ...
By using its proprietary delNS technology, BlueSky Immunotherapies has created a viral vector platform for the induction of interferon and expression of tumor antigens. delNS vectors have many properties for overcoming the immunosuppressive environment of tumors. ...
Key clinical findings from IMA203 Phase 1a trial In the ongoing ACTengine® IMA203 trial, Immatics is treating advanced solid cancer patients utilizing TCR-T cells directed against an HLA-A*02-presented peptide derived from preferentially expressed antigen in melanoma (PRAME). PRAME is homogenously expressed and highly prevalent across several ...